{"name":"Kwang-Ha Yoo","slug":"kwang-ha-yoo","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Bronpass Tab.","genericName":"Bronpass Tab.","slug":"bronpass-tab","indication":"Other","status":"marketed"},{"name":"Placebo of Bronpass Tab.","genericName":"Placebo of Bronpass Tab.","slug":"placebo-of-bronpass-tab","indication":"Other","status":"marketed"},{"name":"Placebo of Erdos capsule","genericName":"Placebo of Erdos capsule","slug":"placebo-of-erdos-capsule","indication":"Other","status":"marketed"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Erdos capsule","genericName":"Erdos capsule","slug":"erdos-capsule","indication":"Attention deficit hyperactivity disorder (ADHD)","status":"marketed"}]}],"pipeline":[{"name":"Bronpass Tab.","genericName":"Bronpass Tab.","slug":"bronpass-tab","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Erdos capsule","genericName":"Erdos capsule","slug":"erdos-capsule","phase":"marketed","mechanism":"Erdos capsule works by inhibiting the reuptake of norepinephrine, a neurotransmitter that plays a key role in attention and arousal.","indications":["Attention deficit hyperactivity disorder (ADHD)"],"catalyst":""},{"name":"Placebo of Bronpass Tab.","genericName":"Placebo of Bronpass Tab.","slug":"placebo-of-bronpass-tab","phase":"marketed","mechanism":"A placebo formulation containing no active pharmaceutical ingredient, used as a control in clinical trials or as a reference standard.","indications":[],"catalyst":""},{"name":"Placebo of Erdos capsule","genericName":"Placebo of Erdos capsule","slug":"placebo-of-erdos-capsule","phase":"marketed","mechanism":"A placebo formulation containing no active pharmaceutical ingredient, used as a control comparator in clinical trials.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBlb2ZLRGVTdksteEE0VEt1X1dTZlYtV1l4WFZCM2hTTjFFaUp6bFkzRXVKZHk3WWhBMjBZWElaNVAwQXZhdzZwcUV5WVJQdHk2TDdtUVZtN0xROHpfaEpz?oc=5","date":"2024-07-03","type":"pipeline","source":"nature.com","summary":"Clinical characteristics of chronic obstructive pulmonary disease patients with superoptimal peak inspiratory flow rate - nature.com","headline":"Clinical characteristics of chronic obstructive pulmonary disease patients with superoptimal peak inspiratory flow rate","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"marketed":4},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}